Table 1.
Treatment | Dose/0.1 mL/plate | TA 100 (without S9)% Inhibition | TA 98 (without S9) % Inhibition | TA 100 (with S9) % Inhibition | TA 98 (with S9) % Inhibition |
---|---|---|---|---|---|
Co-incubation | 25 µg | 42.01 ± 4.25b | 23.07 ± 3.42c | 53.02 ± 5.71c | 40.40 ± 3.42c |
50 µg | 50.69 ± 4.24b | 39.92 ± 3.76b | 66.85 ± 1.66b | 50.35 ± 2.05b | |
100 µg | 65.71 ± 2.48a | 50.98 ± 1.65ab | 74.48 ± 2.59ab | 60.37 ± 1.40a | |
250 µg | 74.47 ± 2.51a | 58.97 ± 1.81a | 83.37 ± 1.21a | 61.51 ± 2.08a | |
Pre-incubation | 25 µg | 49.77 ± 2.88c | 35.53 ± 2.79c | 60.91 ± 2.01c | 46.39 ± 2.45c |
50 µg | 60.51 ± 2.06b | 47.60 ± 2.76b | 70.66 ± 3.44b | 57.74 ± 1.79b | |
100 µg | 75.28 ± 2.91a | 58.79 ± 1.74a | 85.01 ± 1.11a | 73.43 ± 3.45a | |
250 µg | 82.30 ± 1.63a | 62.85 ± 3.33a | 91.41 ± 1.26a | 82.56 ± 2.24a |
Values are represented as Mean ± SE, level of significance p ≤ 0.05. Means with different superscripts represent significant difference among them in all groups.